Delsitech Ltd

30/08/2024

We are honored to be recognized by our hometown once again with the "Growth in Sight" award as a part of the Turku Europe Forum Event 2024. The award acknowledges Delsitech Ltds significant potential for future growth, but also the notable positive impact we are able to have on the growth and development opportunities of our local community. Read more from the link below:

Turku, Finland – 30th August 2024: DelSiTech Ltd, a clinical stage Finnish drug delivery and drug development company, today announced receiving of the Entrepreneurial Spirit of Turku "Growth in Sight" award as part of the Turku Europe Forum Event 2024. In the Growth in Sight category, the recipie...

23/05/2024

💉 Delsitech Ltd is thrilled to announce an exclusive licensing agreement with a leading global pharmaceutical company!

This exclusive agreement grants them rights to our groundbreaking controlled release technology for the development and commercialization of an undisclosed long-acting injectable drug product. Under the terms of the agreement, will receive an upfront payment of $9M and potential milestone payments exceeding $200M, plus royalties on net sales.

This is the second global license agreement to be announced by DelSiTech in 2024 and we look forward to sharing more updates in the future. Read the full press release from the link below.

13/02/2024

Delsitech Ltd is thrilled to announce a global license and development agreement with Tolmar, marking a significant milestone in our partnership since their investment in January 2024.

Under the terms of the agreement, will obtain a global license to utilize ’s proprietary Silica Matrix technology for two undisclosed drug targets. In addition, both companies will collaborate to expand the development of additional drug products across a range of therapeutic areas.

This further strengthens our partnership with Tolmar and holds immense promise for innovative solutions. We look forward to sharing more updates in the future.

Read more about the collaboration here: https://bit.ly/4bE2ayg

16/01/2024

We are pleased to announce the successful completion of a EUR 10 million financing round, the largest single financing round in the Company’s history.

The financing was co-led by new investors Venture Capital LLC and International Ltd, with participation from existing Delsitech Ltd shareholders.

Funds will be used to advance ’s proprietary silica-based drug delivery technology platform and expand its in-house manufacturing capability to support the development programs of multiple partners.

We look forward to sharing further updates as we continue to address high unmet and needs for the benefit of patients.

Read more about the financing, here: http://bit.ly/47DjFLS

01/12/2023

As winter arrives, we find ourselves reflecting on this autumns successful events. Thank you to all of our partners for their support and dedication to development of long-acting therapies this year at Bio Europe.

29/06/2023

Delsitech Ltd is excited to announce positive topline clinical data from a phase 1 trial for our sustained release eye drop platform. Find out more below.

Turku, Finland – 29th June 2023: Drug delivery and development company DelSiTech today reported positive topline results from its Phase 1 clinical trial, evaluating the safety and tolerability of DST-2105, DelSiTech’s first of its kind, silica-based, long-acting demulcent eye drop product. DST-2...

31/05/2023

Delsitech Ltd is pleased to announce completion of a cleanroom facility for aseptic manufacturing! The state of the art facility will continue to accelerate the development of important treatments for both us and our partners.

DelSiTech is pleased to announce today the opening of a cleanroom facility of the highest standard for aseptic manufacturing of pharmaceutical products, including sterile injectables. ” The construction of our own sterile manufacturing unit marks a significant turning point in the DelSiTech story....

15/03/2023

Delsitech Ltd is proud to announce a new collaboration with the Gates Foundation for the development of sustained release human immunodeficiency virus (HIV) vaccines. Read more at https://bit.ly/3YQkBIm

Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop long-acting injectable formulations ensuring the slow release of human immunodeficiency viru...

06/07/2022

DelSiTech is excited to announce an exclusive agreement with Iveric Bio, Inc. for the development of sustained release Zimura. Find out more below.

Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s sil...

15/03/2022

Finnish Chambers of Commerce has granted 15 year medal of merits to Ari-Pekka Forsback, Mika Jokinen and Mika Koskinen for their long-term work for DelSiTech.

Congratulations!

03/02/2022

DelSiTech is pleased to welcome Mr. Kristian Rantala as our new CFO. He has over 20 years of experience in financial management including several CFO positions and he has previously participated in a successful Nasdaq IPO. https://bit.ly/3AW62c7

Turku, Finland – 3 February 2022: DelSiTech Ltd, a Finnish drug delivery technology and development company announced today that Mr. Kristian Rantala has been appointed to its Chief Financial Officer (CFO), effective as of February 7, 2022. Kristian Rantala has over 20 years of experience in all f...

28/01/2022

DelSiTech Ltd welcomes Dr. Outi Heikkilä, as the new Director, Head of Manufacturing. Her core competences include cleanroom operations, GMP manufacturing, and quality requirements of investigational medicinal products. Please read more at https://bit.ly/3rVrlq9

Finnish drug delivery technology and drug development company DelSiTech Ltd welcomes Dr. Outi Heikkilä, as the new Director, Head of Manufacturing. The new position took effect in January 2022. Dr. Outi Heikkilä comes with a strong scientific background in cell biology and virology, especially on ...

17/09/2021

Description of the position

Your task is to provide analytical support to company’s formulation development projects. You work in project teams as the analytical expert, and you may participate in several development projects at the same time. You are working in close collaboration with other analytical scientists, formulation scientists and project managers. Your daily work consists of analytical method development, conducting analyses and dissolution tests as well as reporting of the results to supervisors and project managers. An important part of the job is to interact with our partners’ development teams worldwide.

Requirements

An ideal candidate for this position should have an academic educational background e.g., in chemistry, biochemistry or material sciences and some working experience in the pharma/biotech industry or academy in the field of analytics or drug development. Previous knowledge in analytical methods such as liquid chromatography, immunoassays or protein analytics is highly appreciated. You are familiar with writing documents and reports. Good oral and written communication in English is mandatory. Most importantly, you are highly motivated to learn new skills, fast learner and able to work under pressure.

We offer

We offer a unique opportunity to join a rapidly growing drug development and drug delivery technology company with a highly interesting global business. In this position you will be able to become a true expert in analytics as well as a drug development professional with excellent prospects to move ahead in your career. As a small dynamic company, we have a great working climate and co-workers with common values and mutual trust. We offer a competitive salary and benefits.

Interested?

Please send your application and CV to info@delsitech.com by 27 September, 2021. For additional information please call Head of Analytical Development, Marceline Akieh-Pirkanniemi, tel. + 358 458684245. Please leave a voice message, if not answered immediately.

17/09/2021

Description of the position

As the Head of Manufacturing, you are responsible for setting up and developing drug intermediate and final drug product manufacturing activities in DelSiTech, first in non-GMP environment and later on under GMP. You are expected to build up successfully an integral part of the company operations in the next 12 months and participate in recruitment of the manufacture personnel. You are the company champion in sterile product manufacture and manufacture related technical and quality aspects. Your task is to provide the best manufacture solutions for in-house product opportunities as well as our partner projects. You are in daily contact with our partners’ development and manufacture teams worldwide regarding manufacture processes. You also support business development efforts as the key manufacture expert. Naturally, you belong to the company management team amongst the other Directors.

Requirements

To be successful in this position, we expect you to have strong working experience in the pharma/biotech industry in manufacture of sterile drug products. Knowledge in operating in GMP environment is essential, and previous experience in interactions with regulatory authorities for GMP related issues is highly appreciated. A great plus would be know-how on spray drying or drug delivery technologies. You are familiar with writing regulatory documents, such as batch records and IMPDs. Your educational background should be e.g., in technology, pharmacy or other relevant science, and a PhD/DSc degree is seen as an advantage, but not necessary. You are truly co-operative and also understand the business of DelSiTech. Good oral and written communication in English is mandatory. You are ready to travel for business if needed. You have previous experience in supervising manufacture professionals, and your leading style is goal-oriented, supportive, and inspiring.

We offer

We offer a unique opportunity to join a rapidly growing drug development and drug delivery technology company with a highly interesting global business. In this position, you will be able to grow as a leader and drug development professional and make a difference in your work. As a small dynamic company, we have a great working climate and co-workers with common values and mutual trust. We offer a competitive salary and benefits.

Interested?

Please send your application and CV to info@delsitech.com by 27 September, 2021. For additional information please call CEO, Lasse Leino, tel. +358 408494694. Please leave a voice message, if not answered immediately.

17/09/2021

Description of the position

As a Project Manager you are leading multiple projects and cross-scientific project teams which work in close collaboration with our partners worldwide to develop novel controlled release drug products. You are responsible for planning and implementation of operational tasks in the projects and their timely conduct together with the project teams. You are daily in contact with our partners’ development teams and report the progress of the projects both in-house as well as to partners outside. You belong to DelSiTech Project Management Team together with other company Project Managers.

Requirements

To be successful in this position we expect you to have a previous working experience in a pharma/biotech/life science organisation in project management. An advantage would be know-how on drug development or drug delivery technologies. You are familiar with periodic reporting both orally and in writing. You have an academic educational background e.g., in biosciences, pharmacy, natural sciences or technology. You understand also the business of DelSiTech and your own role to support the business. Fluent oral and written communication and presentation skills in English are mandatory. You are ready to travel for business if needed. As a person, you are team-player and work effectively even under pressure. Your leading style is goal-oriented, supporting and inspiring.

We offer

We offer a unique opportunity to join a rapidly growing drug development/drug delivery technology company with a highly interesting global business. In this position you will be able to grow as a leader and drug development professional, with excellent prospects to move ahead in your career. As a small dynamic company, we have a great working climate and co-workers with common values and mutual trust. We offer a competitive salary and benefits.

Interested?

Please send your application and CV to info@delsitech.com by 27 September, 2021. For additional information please call CEO, Lasse Leino, tel. +358 408494694. Please leave a voice message, if not answered immediately.

07/01/2021

Delsitech Ltd is pleased to announce the appointment of Dr. Sakari Karhuvaara, as our new Medical Director.

Please find the full press release here: https://bit.ly/2Xl7ku5

Dr. Sakari Karhuvaara, Medical Director Finnish drug delivery technology and drug development company DelSiTech Ltd announces and welcomes Dr. Sakari Karhuvaara, as the new Medical Director. The position took effect in the beginning of January 2021, upon the retirement of the previous Medical Direct...

23/09/2020

Delsitech Ltd osallistui elokuun lopussa pidettyyn kolmanteen Turun Eurooppa-Foorumiin ja sen paneelikeskusteluun Turun terveysklusterin roolista alueen talousveturina. DelSiTechin toimitusjohtaja Lasse Leino piti tilausuudessa lyhyen alustuksen lääkekehityksen haasteista ja mahdollisuuksista Turussa. Katso esitys videona tästä.

27/08/2020

We are proud to announce that DelSiTech has been awarded the Entrepreneurial Spirit of Turku 2020 award for our strong international standing.

Find out more: https://bit.ly/3hDzr0c

Dr. Lasse Leino, Chief Executive Officer at DelSiTech Ltd. Turku, Finland – 27th August 2020: DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced receiving of the Entrepreneurial Spirit of Turku "Born Global" award as part of the Turku Europe Forum Event 2020. The ...